Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin ... see more

NEO:FH - Post Discussion

Filament Health Corp > 1-for-10 rollback
View:
Post by lscfa on Aug 15, 2023 11:01am

1-for-10 rollback

Filament shareholders only get 20,600,000 shares in merged co. This is 1/10 of FH shares o/s.     




https://www.sec.gov/Archives/edgar/data/1988363/000121390023067070/ff42023_1427702bcltd.htm

Comment by lscfa on Aug 15, 2023 11:23am
Jupiter has $217 mil Cdn cash & securities but assuming 90% redemptions and $13.3 mil transaction costs so only $7 mil cdn cash after RTO and total of 29.3 mil shs o/s
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities